Sydney, Feb 15, 2026, 16:59 AEDT — Market closed.
- CSL wrapped up Friday at A$150.01, falling 1.4% in the session and sliding roughly 17% for the week.
- Earlier in the week, the company delivered a lackluster half-year update and unexpectedly swapped out its CEO—catalysts for the sell-off that followed.
- Coming up: brokers weigh in once trading picks up Monday, plus that March ex-dividend date is still ahead.
CSL Ltd slid 1.4% on Friday to finish at A$150.01, marking its fourth consecutive drop and pushing shares close to their 52-week lows. The Australian exchange won’t open again until Monday. 1
The pain spread well past one stock. This week, Australia’s healthcare sub-index dropped 12.6%, its steepest slide since mid-March 2020—even though strong earnings powered the overall market to its sharpest weekly gain in ten months, according to a Reuters wrap. “Led by the miners and banks,” wrote AMP chief economist Shane Oliver. VanEck Australia’s Jamie Hannah pointed to profit-taking after sharp intraday swings. 2
CSL moves the needle for Australian healthcare stocks—it’s the heavyweight most portfolios lean on for global growth. A drop in CSL lands hard across the sector, and sentiment can flip quickly, particularly during reporting season.
CSL reported a 4% drop in first-half revenue to $8.3 billion earlier in the week, with NPATA — the company’s preferred metric — down 7% to $1.9 billion. The group bumped its buyback up to $750 million, keeping its full-year outlook unchanged: revenue growth of 2% to 3% and NPATA growth between 4% and 7% on a constant-currency basis, which excludes the impact of exchange rates. 3
Some analysts say the sell-off has already overshot what the fundamentals warrant. Shane Ponraj at Morningstar called the market’s stance on plasma gross margins “overly pessimistic,” adding he’s looking for margin gains and cost-cutting to take on a bigger role down the line. 4
This near-term stretch isn’t pretty—risks are front and center. CSL posted net profit after tax of $384 million for the six months ended Dec. 31. That’s a sharp drop from $2 billion the year before. The company also signaled around $1.1 billion in after-tax impairments, mostly linked to Vifor and Seqirus restructuring charges. “I’m not prepared to accept that we can’t do better,” interim chief Gordon Naylor told analysts on the call. Citi, for its part, flagged how tight things look: Behring has to shoulder much of the load in the back half, and there’s not a lot of room for missteps. 5
Once trading picks up again on Monday, the focus shifts to whether the stock can stabilize—or if fresh model cuts will hit, with brokers having already adjusted for a softer first half. Investors will be weighing the speed of buybacks, any hints about the CEO search, and whether Behring can put sales back on track. Those specifics may end up moving sentiment more than anything happening across the broader market.
Here’s how the dividend timeline shakes out: CSL shares go ex-dividend March 10. Record date lands right after, on March 11, and shareholders get paid April 9. Full-year results? Mark August 18. 6
